AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive

Related Keywords

Australia ,United States ,Switzerland ,Australian ,Corey Davis ,Gary Waanders ,Eli Lilly ,Chris Maggos ,Andrea Pfeifer ,Head Of Investor Relations Corporate Communications ,Alzheimer Disease Neuroimaging Initiative ,Genentech ,Us Food Drug Administration ,International Media ,Alzheimer Disease Cooperative Study ,Janssen Pharmaceuticals Inc ,Johnson ,Roche Group ,Cohesion Bureau ,Disease Advances ,Janssen Pharmaceuticals ,Biologics License Application ,Drug Administration ,Australian Imaging ,Lifestyle Flagship Study ,Disease Neuroimaging Initiative ,Disease Cooperative Study ,Taut Helper ,Investor Relations ,Ac Immune ,Alzheimers Disease ,Ac Immune Sa ,Phosphorylated Tau ,Clinical Study ,Ctive Immunization ,Immunotherapy ,Neurodegenerative Diseases ,Clinical Symptoms ,Tau Pathology ,Mmunotherapies ,